Opportunity Title: FDA Fellowship - Diabetes Therapeutics
Opportunity Reference Code: FDA-CBER-2026-0089

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CBER-2026-0089

How to Apply ***To submit your application, scroll to the bottom of this opportunity and click APPLY.***

A complete application consists of:

- An application
- Transcripts – Click here for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.

Application Deadline 1/15/2027 3:00:00 PM Eastern Time Zone

Description ***Applications will be reviewed on a rolling-basis.**


FDA Office and Location: A research opportunity is currently available at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), located at White Oak, Maryland.

The ORISE Research Participation Program at the U.S. Food and Drug Administration is an educational and training program designed to provide college students, recent graduates, and university faculty opportunities to connect with the unique resources of the FDA. With the support of an assigned mentor, participants have authentic hands-on research experience and allows them access to unique research opportunities, top scientists and engineers, and state-of the art facilities and equipment. The Center for Biologics Evaluation and Research (CBER) is one Center within the Food and Drug Administration, an Agency within the United States Government's Department of Health and Human Services. CBER's mission is to protect and enhance the public health through the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies.

Research Project: Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic ß-cells, lifelong exogenous insulin dependence, and risks of severe hypoglycemia and microvascular complications. There is an important gap in established clinical endpoints that can provide reasonable prediction of clinical outcomes. The project will focus on computational analysis of datasets as well as validations of the finding in the lab.

Learning Objectives:

OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION
ORISE GO



The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO
GET IT ON Google Play
Download on the App Store

Opportunity Title: FDA Fellowship - Diabetes Therapeutics
Opportunity Reference Code: FDA-CBER-2026-0089

1. Handle several datasets on various parameters related to diabetes
2. Learn how to avoid duplications in analyzing large data sets
3. Learn various stat tolls
4. Validate in the lab computational findings

Mentor: The mentor for this opportunity is Chava Kimchi-Sarfaty (Chava.Kimchi-Sarfaty@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentor.

Anticipated Appointment Start Date: Winter, 2026/2027. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

Participant Stipend: The participant will receive a monthly stipend commensurate with educational level and experience.

Citizenship Requirements: This opportunity is available to U.S. citizens and Lawful Permanent Residents (LPR) only.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

Qualifications The qualified candidate should have received, or be currently pursuing, a doctoral degree in the one of the relevant fields.

Preferred skills:

- Computational skills
- Wet lab skills

Point of Contact Richard

Eligibility Requirements

- **Citizenship:** LPR or U.S. Citizen
- **Degree:** Doctoral Degree.
- **Discipline(s):**

Opportunity Title: FDA Fellowship - Diabetes Therapeutics
Opportunity Reference Code: FDA-CBER-2026-0089

- **Life Health and Medical Sciences** (51 👁)

Affirmation I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)